BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 36238135)

  • 1. Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments.
    Gordon A; Johnston E; Lau DK; Starling N
    Onco Targets Ther; 2022; 15():1183-1196. PubMed ID: 36238135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration.
    Ooki A; Yamaguchi K
    Gastric Cancer; 2021 Nov; 24(6):1169-1183. PubMed ID: 34398359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Tumor DNA Analysis Detects
    Jogo T; Nakamura Y; Shitara K; Bando H; Yasui H; Esaki T; Terazawa T; Satoh T; Shinozaki E; Nishina T; Sunakawa Y; Komatsu Y; Hara H; Oki E; Matsuhashi N; Ohta T; Kato T; Ohtsubo K; Kawakami T; Okano N; Yamamoto Y; Yamada T; Tsuji A; Odegaard JI; Taniguchi H; Doi T; Fujii S; Yoshino T
    Clin Cancer Res; 2021 Oct; 27(20):5619-5627. PubMed ID: 34376535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer.
    Lau DK; Collin JP; Mariadason JM
    Biomedicines; 2024 May; 12(5):. PubMed ID: 38791079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?
    Hierro C; Alsina M; Sánchez M; Serra V; Rodon J; Tabernero J
    Ann Oncol; 2017 Jun; 28(6):1207-1216. PubMed ID: 28327938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting of fibroblast growth factor receptors in gastric cancer.
    Inokuchi M; Fujimori Y; Otsuki S; Sato Y; Nakagawa M; Kojima K
    Gastroenterol Res Pract; 2015; 2015():796380. PubMed ID: 26000013
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
    Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design.
    Catenacci DV; Tesfaye A; Tejani M; Cheung E; Eisenberg P; Scott AJ; Eng C; Hnatyszyn J; Marina N; Powers J; Wainberg Z
    Future Oncol; 2019 Jun; 15(18):2073-2082. PubMed ID: 31094225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
    Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
    Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study.
    Yasui H; Takeno A; Hara H; Imamura H; Akamatsu H; Fujitani K; Nakane M; Kondoh CN; Yukisawa S; Nasu J; Miyata Y; Makiyama A; Ishida H; Yoshida N; Matsumura E; Ishigami M; Sugihara M; Ochiai A; Doi T
    Int J Colorectal Dis; 2022 Jun; 37(6):1393-1402. PubMed ID: 35585358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutic target molecules for gastric and gastroesophageal junction cancer.
    Kawakami H
    Int J Clin Oncol; 2024 Apr; ():. PubMed ID: 38630383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers.
    Hur JY; Chao J; Kim K; Kim ST; Kim KM; Klempner SJ; Lee J
    Pathol Res Pract; 2020 Apr; 216(4):152878. PubMed ID: 32089408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
    Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
    Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.
    Kim SY; Ahn T; Bang H; Ham JS; Kim J; Kim ST; Jang J; Shim M; Kang SY; Park SH; Min BH; Lee H; Kang WK; Kim KM; Park W; Lee J
    Oncotarget; 2017 Feb; 8(9):15014-15022. PubMed ID: 28122360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer.
    Xiang H; Chan AG; Ahene A; Bellovin DI; Deng R; Hsu AW; Jeffry U; Palencia S; Powers J; Zanghi J; Collins H
    MAbs; 2021; 13(1):1981202. PubMed ID: 34719330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
    Van Cutsem E; Bang YJ; Mansoor W; Petty RD; Chao Y; Cunningham D; Ferry DR; Smith NR; Frewer P; Ratnayake J; Stockman PK; Kilgour E; Landers D
    Ann Oncol; 2017 Jun; 28(6):1316-1324. PubMed ID: 29177434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer.
    Kahraman S; Yalcin S
    Onco Targets Ther; 2021; 14():4149-4162. PubMed ID: 34285507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.